Baidu
map

EHJ:直接PCI术中血栓抽吸可降低STEMI患者死亡率

2012-10-03 张一宸译 医学论坛网

     9月17日《欧洲心脏杂志》(Eur Heart J)发表一项针对真实世界的非选择性ST段抬高心肌梗死患者(STEMI)的研究,结果表明尤其对于总缺血时间较短的患者,直接经皮冠脉介入治疗(PPCI)术中行血栓抽吸可显著降低死亡率。  研究者于2008-2011年间共搜集2567例接受PPCI治疗的STEMI 患者。采用Cox比例风险模型和多元逻辑回归分析校正

  血栓抽吸

  9月17日《欧洲心脏杂志》(Eur Heart J)发表一项针对真实世界的非选择性ST段抬高心肌梗死患者(STEMI)的研究,结果表明尤其对于总缺血时间较短的患者,直接经皮冠脉介入治疗(PPCI)术中行血栓抽吸可显著降低死亡率。
  研究者于2008-2011年间共搜集2567例接受PPCI治疗的STEMI 患者。采用Cox比例风险模型和多元逻辑回归分析校正已知协变量。1095例患者接受血栓切除术(42.7%)。血栓摘除组患者PPCI术后溶栓更易达到3级血流[校正比值比(OR)1.92, 95%置信区间(CI): 1.34–2.76, P=0.0004]。血栓切除显著降低住院[校正OR: 0.51, 95% CI: 0.29–0.93, P=0.027]及较长期死亡率[校正危险比(HR):0.69, 95% CI: 0.48–0.96, P=0.028]。倾向加权分析接受血栓切除术的患者较长期死亡率校正HR为0.43 (95% CI: 0.19–0.97; P=0.042)。血栓切除和降低较长期死亡率相关性在总缺血时间≤180min的患者中有显著意义(P=0.001),在缺血时间>180 min患者中无显著意义。(P=0.99)。

  链接:

Noman A, Egred M, Bagnall A, Spyridopoulos I, Jamieson S, Ahmed J.Impact of thrombus aspiration during primary percutaneous coronary intervention on mortality in ST-segment elevation myocardial infarction. Eur Heart J. 2012 Sep 17



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641488, encodeId=6a0d1641488dc, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Tue Sep 17 11:04:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936678, encodeId=f41619366e88f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 09 15:04:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983397, encodeId=75df198339eb1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 28 10:04:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633796, encodeId=f2c81633e963c, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Oct 21 02:04:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749106, encodeId=06f01e4910665, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Thu Mar 07 21:04:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481788, encodeId=49b71481e88b6, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Oct 05 01:04:00 CST 2012, time=2012-10-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641488, encodeId=6a0d1641488dc, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Tue Sep 17 11:04:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936678, encodeId=f41619366e88f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 09 15:04:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983397, encodeId=75df198339eb1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 28 10:04:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633796, encodeId=f2c81633e963c, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Oct 21 02:04:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749106, encodeId=06f01e4910665, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Thu Mar 07 21:04:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481788, encodeId=49b71481e88b6, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Oct 05 01:04:00 CST 2012, time=2012-10-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641488, encodeId=6a0d1641488dc, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Tue Sep 17 11:04:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936678, encodeId=f41619366e88f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 09 15:04:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983397, encodeId=75df198339eb1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 28 10:04:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633796, encodeId=f2c81633e963c, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Oct 21 02:04:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749106, encodeId=06f01e4910665, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Thu Mar 07 21:04:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481788, encodeId=49b71481e88b6, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Oct 05 01:04:00 CST 2012, time=2012-10-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641488, encodeId=6a0d1641488dc, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Tue Sep 17 11:04:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936678, encodeId=f41619366e88f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 09 15:04:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983397, encodeId=75df198339eb1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 28 10:04:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633796, encodeId=f2c81633e963c, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Oct 21 02:04:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749106, encodeId=06f01e4910665, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Thu Mar 07 21:04:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481788, encodeId=49b71481e88b6, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Oct 05 01:04:00 CST 2012, time=2012-10-05, status=1, ipAttribution=)]
    2012-10-21 zxl736
  5. [GetPortalCommentsPageByObjectIdResponse(id=1641488, encodeId=6a0d1641488dc, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Tue Sep 17 11:04:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936678, encodeId=f41619366e88f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 09 15:04:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983397, encodeId=75df198339eb1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 28 10:04:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633796, encodeId=f2c81633e963c, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Oct 21 02:04:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749106, encodeId=06f01e4910665, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Thu Mar 07 21:04:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481788, encodeId=49b71481e88b6, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Oct 05 01:04:00 CST 2012, time=2012-10-05, status=1, ipAttribution=)]
    2013-03-07 xuyu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1641488, encodeId=6a0d1641488dc, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Tue Sep 17 11:04:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936678, encodeId=f41619366e88f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 09 15:04:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983397, encodeId=75df198339eb1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 28 10:04:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633796, encodeId=f2c81633e963c, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Oct 21 02:04:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749106, encodeId=06f01e4910665, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Thu Mar 07 21:04:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481788, encodeId=49b71481e88b6, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Oct 05 01:04:00 CST 2012, time=2012-10-05, status=1, ipAttribution=)]

相关资讯

Circulation:STEMI病人PCI术前应用山莨菪碱或预防造影剂肾病

    我国河北医科大学附属第二医院研究人员在2012年世界心脏病学大会上报告的一项研究显示:ST段抬高型心肌梗死(STEMI)病人直接经皮冠状动脉介入(PCI)术前静脉输注山莨菪碱,有可能预防造影剂肾病(CIN)的发生。       CIN是PCI术后最严重的并发症之一。接受直接PCI的急性心肌梗死病人发生CIN的风险较大。山莨菪碱是从中草药

北京STEMI病人PCI使用率较其他国家低

  2012年世界心脏病学大会(4月18~21日,阿联酋迪拜)上公布的我国北京市心肺血管疾病研究所、北京安贞医院的研究人员开展的一项研究显示:与其他国家相比,在中国经济最发达的地区——北京,ST段抬高型急性心肌梗死(STEMI)病人的经皮冠状动脉介入术(PCI)使用率仍较低。STEMI病人的医疗质量存在很大差距,尤其是北京的二级医院。   虽然指南推荐用PCI治疗S

术前高剂量他汀可预防PCI相关炎症和心肌损伤

  2012年世界心脏病学大会于4月18~21日在阿联酋迪拜召开,会上公布了我国北京大学第三医院研究人员开展的一项研究。该研究表明,于经皮冠脉介入(PCI)术前给予48小时的阿托伐他汀80 mg治疗可抑制PCI相关炎症,且对心肌具有一定的保护作用;高剂量与低剂量的阿托伐他汀组在安全性方面没有差异。   研究中,86例行PCI的冠心病(CHD)患者被随机分为对照组(n=30)、低剂

CTO病变经桡动脉入路行ad hoc PCI可行

  2012年世界心脏病学大会公布埃及和我国台湾学者共同开展的一项研究显示:对于慢性完全闭塞(CTO)的病人,经桡动脉入路行ad hoc经皮冠状动脉介入术(PCI)是安全和可行的,成功率和住院转归均可接受。   Ad hoc PCI已成为临床惯例。但还没有人着重研究ad hoc CTO PCIs。为此,作者比较了Ad h

STEMI病人PCI术前应用山莨菪碱或预防造影剂肾病

  我国河北医科大学附属第二医院研究人员在2012年世界心脏病学大会上报告的一项研究显示:ST段抬高型心肌梗死(STEMI)病人直接经皮冠状动脉介入(PCI)术前静脉输注山莨菪碱,有可能预防造影剂肾病(CIN)的发生。   CIN是PCI术后最严重的并发症之一。接受直接PCI的急性心肌梗死病人发生CIN的风险较大。山莨菪碱是从中草药中提取的一种生物碱,广泛用于治疗感染性休克、急性肾小球肾炎和糖尿

联用抗血小板药与VKA增加伴心梗或PCI的房颤患者的出血风险

  丹麦学者的一项研究表明:在伴心肌梗死或接受经皮冠脉介入治疗(PCI)的房颤患者中,抗血小板药与维生素K拮抗剂(VKA)的任意二重或三重联合均与患者的早期出血率升高相关;在房颤伴缺血性心脏病患者中进行抗血栓联合治疗时应慎重权衡其益处和风险。论文发表于《美国心脏病学会杂志》[J Am Coll Cardiol 2012, 59:512]。

Baidu
map
Baidu
map
Baidu
map